Product Description: Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity[1][2][3].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C194H312N54O59S2
References: [1]Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440./[2]Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194./[3]Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325.
CAS Number: 1415456-99-3
Molecular Weight: 4409.01
Compound Purity: 98.59
Research Area: Metabolic Disease
Solubility: 10 mM in DMSO
Target: CGRP Receptor
English
Deutsch
